Diabetes
News from the FDA/CDC
FDA approves tirzepatide for treating obesity
Zepbound should go to market in the United States by year’s end, with an anticipated monthly list price of $1,060.
Latest News
EMR prompt boosts albuminuria measurement in T2D
An EMR prompt in primary care to measure albuminuria and eGFR in adults with type 2 diabetes boosted screening by about 50%.
From the Journals
Insulin appears less heat-sensitive than previously thought
Although the issue of insulin refrigeration is less urgent in higher-income countries, it does arise when people accidentally leave their unopened...
From the Journals
Does diabetes affect colorectal cancer outcomes?
“Preventing diabetes complications may help improve survival in patients with CRC, especially [in] female patients and those in the early stages...
Latest News
More evidence metformin may be neuroprotective
Adults who stopped metformin early were 21% more likely to be diagnosed with dementia during follow-up.
Latest News
Semaglutide prescribing surged in the past year
General and family practice providers were the most frequent semaglutide providers (30%), followed by internists (15%).
Conference Coverage
Beyond semaglutide, a coming pipeline of new antiobesity meds
With the two highest doses of retatrutide, 100% of participants lost ≥ 5% of weight. “I’m not sure how many other times I will ever be able to say...
From the Journals
Another study ties statins to T2D: Should practice change?
“When using rosuvastatin over atorvastatin, we ... emphasize the importance of meticulous monitoring and appropriate lifestyle interventions to...
From the Journals
More weight loss with time-restricted eating
“Our findings ... show that TRE is safe in patients who are using either diet alone or medications to control their [type 2 diabetes].”
From the Journals
Obesity boosts gestational diabetes risk in women with PCOS
Prepregnancy insulin resistance is common among women with PCOS and may play a major part in the pathogenesis of gestational diabetes.
Conference Coverage
SGLT2 inhibitors in type 2 diabetes linked to lower risk of developing GI cancers
The study is notable for including people with ulcerative colitis and Crohn’s disease and for evaluating every GI cancer.